1. CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD. (12th June 2019) Authors: Mollaret, E.; Gomez, E.; Nadel, B.; Naiglin, L.; Anquetin, M.; Barau, C.; Baseggio, L.; Bret, C.; Brisou, G.; Brousset, P.; Camara‐Clayette, V.; Cartron, G.; Da Cunha, K.; Dartigues, P.; Dupuis, J.; Ghaleh, B.; Gravelle, P.; Houot, R.; Karmous‐Gadacha, O.; Laurent, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EXCELLENT OUTCOME OF CHILDREN/ADOLESCENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA TREATED WITH LMB-BASED CHEMOTHERAPY WITH RITUXIMAB. (October 2022) Authors: Dourthe, M.; Phulpin, A.; Auperin, A.; Couec, M.; Dartigues, P.; Ducassou, S.; Garnier, N.; Haouy, S.; Leblanc, T.; Lambilliotte, A.; Leruste, A.; Jourdain, A.; Spiegel, A.; Rigaud, C.; Simonin, M.; Bonneau, J.; Verschuur, A.; Plat, G.; Poirée, M.; Buchbinder, N. Journal: Leukemia research Issue: Volume 121(2022)Supplement Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FEASIBILITY AND BENEFIT OF MOLECULARLY‐INFORMED ENROLLMENT INTO EARLY PHASE CLINICAL TRIALS FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Michot, J.; Camara‐Clayette, V.; Detolle, A.; Chahine, C.; Lazarovici, J.; Danu, A.; Bosq, J.; Ghez, D.; Romano‐Martin, P.; Dartigues, P.; Arfi‐Rouche, J.; Bahleda, R.; Rahali, W.; Varga, A.; Baldini, C.; Tselikas, L.; Paume, C.; Lecourt, H.; Cotteret, S.; Vergé, V. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study. Issue 10 (October 2017) Authors: Valmary-Degano, S.; Colpart, P.; Villeneuve, L.; Monnien, F.; M'Hamdi, L.; Lang Averous, G.; Capovilla, M.; Bibeau, F.; Laverriere, M.-H.; Verriele-Beurrier, V.; Ben Rejeb, H.; Dartigues, P.; Hommell-Fontaine, J.; Gilly, F.-N.; Isaac, S.; Mery, E. Journal: European journal of surgical oncology Issue: Volume 43:Issue 10(2017:Oct.) Page Start: 1915 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei. Issue 1 (January 2017) Authors: Delhorme, J.-B.; Honoré, C.; Benhaim, L.; Dumont, F.; Dartigues, P.; Dromain, C.; Ducreux, M.; Elias, D.; Goéré, D. Journal: European journal of surgical oncology Issue: Volume 43:Issue 1(2017:Jan.) Page Start: 159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Molecular landscape of relapse/refractory diffuse large B‐cell lymphoma. (June 2017) Authors: Michot, J.; Camara‐Clayette, V.; Chahine, C.; Lazarovici, J.; Bosq, J.; Ghez, D.; Dartigues, P.; Danu, A.; Arfi‐Rouche, J.; Tselikas, L.; Ba, B.; Cotteret, S.; Rahali, W.; Vergé, V.; Ribrag, V. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 279 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗